Are stentless valves hemodynamically superior to stented valves? Long-term follow-up of a randomized trial comparing Carpentier–Edwards pericardial valve with the Toronto Stentless Porcine Valve  by Cohen, Gideon et al.
A
C
D
Acquired Cardiovascular Disease Cohen et alAre stentless valves hemodynamically superior to stented valves?
Long-term follow-up of a randomized trial comparing Carpentier–
Edwards pericardial valve with the Toronto Stentless Porcine ValveGideon Cohen, MD, PhD, Brandon Zagorski, MSc, George T. Christakis, MD, Campbell D. Joyner, MD,
Jessica Vincent, Jeri Sever, Sumaya Harbi, MD, Randi Feder-Elituv, Fuad Moussa, MD,
Bernard S. Goldman, MD, and Stephen E. Fremes, MDFrom th
and th
Disclosu
Support
Read at
Surge
Receive
public
848Objective: The benefit of stentless valves remains in question. In 1999, a randomized trial comparing
stentless and stented valves was unable to demonstrate any hemodynamic or clinical benefits at 1 year
after implantation. This study reviews long-term outcomes of patients randomized in the aforementioned
trial.
Methods: Between 1996 and 1999, 99 patients undergoing aortic valve replacement were randomized to re-
ceive either a stented Carpentier–Edwards pericardial valve (CE) (Edwards Lifesciences, Irvine, Calif) or a Tor-
onto Stentless Porcine Valve (SPV) (St Jude Medical, Minneapolis, Minn). Among these, 38 patients were
available for late echocardiographic follow-up (CE, n ¼ 17; SPV, n ¼ 21). Echocardiographic analysis was
undertaken both at rest and with dobutamine stress, and functional status (Duke Activity Status Index) was
compared at a mean of 9.3 years postoperatively (range, 7.5–11.1 years). Clinical follow-up was 82% com-
plete at a mean of 10.3 years postoperatively (range, 7.5–12.2 years).
Results: Preoperative characteristics were similar between groups. Effective orifice areas increased in both
groups over time. Although there were no differences in effective orifice areas at 1 year, at 9 years, effective
orifice areas were significantly greater in the SPV group (CE, 1.49  0.59 cm2; SPV, 2.00  0.53 cm2; P ¼
.011). Similarly, mean and peak gradients decreased in both groups over time; however, at 9 years, gradients
were lower in the SPV group (mean: CE, 10.8  3.8 mm Hg; SPV, 7.8  4.8 mm Hg; P ¼ .011; peak: CE,
20.4  6.5 mm Hg; SPV, 14.6  7.1 mm Hg; P ¼ .022). Such differences were magnified with dobutamine
stress (mean: CE, 22.7  6.1 mm Hg; SPV, 15.3  8.4 mm Hg; P ¼ .008; peak: CE, 48.1  11.8 mm Hg;
SPV, 30.8  17.7 mm Hg; P ¼ .001). Ventricular mass regression occurred in both groups; however, no
differences were demonstrated between groups either on echocardiographic, magnetic resonance imaging,
or biochemical (plasma B-type [brain] natriuretic peptide) assessment (P ¼ .74). Similarly, Duke Activity
Status Index scores of functional status improved in both groups over time; however, no differences were
noted between groups (CE, 27.5  19.1; SPV, 19.9  12.0; P ¼ .69). Freedom from reoperation at 12 years
was 92%  5% in patients with CEs and 75%  5% in patients with SPVs (P ¼ .65). Freedom from valve-
related morbidity at 12 years was 82%  7% in patients with CEs and 55%  7% in patients with SPVs
(P ¼ .05). Finally, 12-year actuarial survival was 35%  7% in patients with CEs and 52%  7% in
patients with SPVs (P ¼ .37).
Conclusion: Although offering improved hemodynamic outcomes, the SPV did not afford superior mass re-
gression or improved clinical outcomes up to 12 years after implantation. (J Thorac Cardiovasc Surg
2010;139:848-59)Despite numerous advances in surgical technique, aortic
valve replacement (AVR) for isolated aortic valve disease
does not achieve a normalization of long-term outcomes.1-8
Stentless valves were designed to provide optimal hemody-
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Abbreviations and Acronyms
AI ¼ aortic insufficiency
AVR ¼ aortic valve replacement
BNP ¼ B-type (brain) natriuretic peptide
CE ¼ Carpentier–Edwards (stented) Perimount
valve
CW ¼ continuous wave
DASI ¼ Duke Activity Status Index
EOA ¼ effective orifice area
LV ¼ left ventricular
LVMI ¼ left ventricular mass index
LVOT ¼ left ventricular outflow tract
MRI ¼ magnetic resonance imaging
NYHA ¼ New York Heart Association
PW ¼ pulsed wave
SPV ¼ Toronto Stentless Porcine Valve
2D ¼ 2-dimensional
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completely, resulting in improved survival and functional out-
comes. Finally, optimized hemodynamic profiles and en-
hanced leaflet motion would improve overall valvular
durability and minimize the need for reoperation.10-13
Although such improvements were expected with the ad-
vancements in prosthetic design, much controversy exists
regarding the true hemodynamic and clinical effect of stent-
less valves. To date, numerous comparative studies have
been undertaken.14-17 However, results are disparate, and
no clear clinical advantage of one valve type over another
has been demonstrated.
In 1996, our group attempted to address this ongoing con-
troversy by conducting a randomized trial of stented versus
stentless valves.18 Ninety-nine patients undergoing primary
elective bioprosthetic AVR were randomized to receive
either the Carpentier–Edwards (stented) Perimount valve
(CE; Edwards Lifesciences, Irvine, Calif) or the Toronto
Stentless Porcine Valve (SPV; St Jude Medical, Minneapo-
lis, Minn).
At 1 year postoperatively, although a reduction in peak
and mean transvalvular gradients and an increase in EOAs
was demonstrated in both groups, no differences were noted
between groups. Not unexpectedly, resolution of the under-
lying stenosis resulted in regression of left ventricular (LV)
mass over time in both groups. However, once again, no dif-
ferences were noted between groups. Finally, Duke Activity
Status Index (DASI) scores improved significantly over time
in both groups. Although scores were slightly higher in the
stented group at 3 months postoperatively, no differences
were noted between groups at 1 year postoperatively.
In light of the above findings, we concluded that the
advantages of stentless valves, if any, were unlikely to beThe Journal of Thoracic and Carevealed in the short-term and could only be elucidated
through long-term follow-up of echocardiographic parame-
ters, patient outcomes, and valvular durability. To this end,
we undertook a long-term follow-up of patients randomized
in the aforementioned trial.MATERIALS AND METHODS
A retrospective analysis was undertaken involving patients who par-
ticipated in a prospective randomized trial of stentless (SPV) versus
stented (CE) valves between September 1996 and December 1999 to de-
termine whether implantation of stentless valves resulted in improved
ventricular mass regression, improved hemodynamic indices, and im-
proved clinical outcomes up to 12 years after AVR. Table 1 summarizes
the clinical profiles of all patients by group. Methods of implantation, in-
clusion/exclusion criteria, and randomization protocols have been previ-
ously described.18
Patient Follow-up
Preoperative, postoperative, and 3- and 12-month patient characteristics
were extracted from databases constructed during the initial (1 year) and
follow-up phases of this randomized trial. Appropriate institutional research
ethics board approval was obtained for contacting patients. At first contact,
patients were informed of the study in question and provided initial verbal
consent by telephone. If the patient agreed to participate, the entire process,
including written consent, was repeated during a follow-up office visit.
Clinical Outcomes
Clinical assessment of consented patients was performed in person by
means of physical assessment and facilitated by a standardized postoper-
ative follow-up questionnaire designed to assess current cardiac medica-
tions, New York Heart Association (NYHA) functional status, and
cardiac morbidity, including hospital/outpatient visits and repeat valve
surgery. On receiving the patient’s consent, routine blood work was per-
formed to preclude the presence of confounding variables that might
have adversely affected the patient’s well-being, cardiac function, or
both (eg, anemia or renal insufficiency). Those patients not available
for telephone or echocardiographic follow-up were followed through
linkage of health card numbers to various governmental registries. Be-
cause of Ontario’s ‘‘single-provider’’ health care system, such linkage
offered accurate information regarding mortality, diagnoses, readmis-
sions, and reinterventions.
Valve-related complications were reported according to standardized
methods established by the Society of Thoracic Surgeons and the American
Association of Thoracic Surgeons.19,20 Events were categorized as struc-
tural or nonstructural valve deterioration, valve thrombosis, embolic events,
bleeding events, and/or prosthetic valve endocarditis.
Measurements and Calculations
Two-dimensional echocardiographic protocol and mea-
surements. Transthoracic 2-dimensional (2D) echocardiographic
measurements were performed on all available patients at follow-up,
with comparison with measurements obtained at 3 and 12 months postop-
eratively. Echocardiographic parameters and calculations are provided in
Appendix 1. Examination included 2D, 2D-derived M-mode, and color
Doppler analyses. Left parasternal, apical right parasternal, subcostal,
and suprasternal standard views were used in a successive pattern of inter-
rogation. All measurements were averaged over 3 cardiac cycles in sinus
rhythm, and 6 cardiac cycles were used in cases of atrial fibrillation. Only 2
sonographers were used for this study, both having been previously as-
sessed for less than 5% interobserver variability. All readings were per-
formed by 2 experienced echocardiographers, both of whom wererdiovascular Surgery c Volume 139, Number 4 849
TABLE 1. Preoperative patient characteristics
CE (n ¼ 53) SPV (n ¼ 46) P value
Age (y) 69.0  7.6 71.8  7.1 .07
Age>70 y 24 (45.3%) 29 (63.0%) .1060
Female sex 20 (37.7%) 15 (32.6%) .6754
BSA (m2) 1.86  0.23 1.88  0.24 .7040
Urgent operation 5 (9.4%) 6 (13.0%) .7503
NYHA class III–IV 37 (69.9%) 38 (82.6%) .1634
CHF 8 (15.1%) 6 (13.0%) 1.00
Diabetes 7 (13.2%) 6 (13.0%) .7674
Hypertension 25 (47.2%) 23 (50.0%) .8415
CRF 2 (3.8%) 4 (8.7%) .4122
CCS class III–IV 10 (18.9%) 8 (17.4%) 1.00
COPD 3 (5.7%) 3 (6.5%) 1.00
PVD 6 (11.3%) 6 (13.0%) 1.00
Ejection fraction<40% 4 (7.6%) 4 (8.7%) 1.00
CAD 21 (39.6%) 18 (39.1%) 1.00
Aortic valve lesion
Stenosis 43 (82.7%) 38 (82.6%)
Regurgitation 2 (3.9%) 3 (6.5%)
Mixed 7 (13.4%) 5 (10.9%) .7880
CE, Carpentier–Edwards pericardial bioprosthesis; SPV, Toronto Stentless Porcine
Valve; BSA, body surface area; NYHA, New York Heart Association; CHF, congestive
heart failure; Diabetes, insulin-dependent or non–insulin-dependent diabetes mellitus;
Hypertension, documented history of treatment for hypertension; CRF, chronic renal
failure; CCS, Canadian Cardiovascular Society; COPD, chronic obstructive pulmo-
nary disease; PVD, peripheral vascular disease; CAD, coronary artery disease.
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mean pressure gradients, fractional shortening, cardiac output, and left
ventricular mass index (LVMI) were calculated by using standard formu-
lae. LVMI was estimated by using the criteria of the Canadian Cardiovas-
cular Society.21
Dobutamine stress echocardiographic protocol and
measurements. After baseline echocardiographic assessment was
completed, dobutamine was infused at incremental doses of 5 mg $ kg1 $
min1 every 3 minutes until the target cardiac index was reached (at least
twice baseline). If this was not achieved, dobutamine was gradually in-
creased to a maximum dose of 50 mg $ kg1 $min1. The test was terminated
in cases of hemodynamic instability or excessive patient symptomatology.
The following parameters were recorded at peak cardiac index: peak and
mean pressure transvalvular gradients, ejection fraction, cardiac output,
and EOA.
Dynamic cardiac magnetic resonance imaging protocol
and measurements. A subgroup of randomly selected patients
(CE, n ¼ 15; SPV, n ¼ 15) underwent dynamic cardiac magnetic reso-
nance imaging (MRI) to quantify LV mass and coronary flow reserve.
LV function was assessed by using a well-validated cardiac imaging pro-
tocol known as steady-state free precession.22 A stack of 2D images cov-
ering the heart was acquired, and the cardiac borders were
semiautomatically traced to calculate the LV mass, stroke volume, and
ejection fraction. Annular motion and stiffness were measured by using
a time-resolved MRI tagging sequence,23 and velocity-sensitive (phase
contrast) MRI was used to measure annular motion.24 The same veloc-
ity-sensitive sequence was also used to quantify disorderly flow conditions
distal to the valve in the ascending aorta.
DASI. The DASI is a disease-specific quality-of-life instrument that has
been highly correlated with peak oxygen uptake (Spearman correlation co-
efficient ¼ 0.58).25 This brief, self-administered, 12-item questionnaire is
a reliable and valid measure of functional status and exercise capacity. Var-850 The Journal of Thoracic and Cardiovascular Surgious spheres of daily activity are assessed, with possible scores ranging from
0 to 58.2 points. The questionnaire was administered to patients at follow-
up, with comparison with scores obtained at 3 and 12 months postopera-
tively.
Plasma B-type (brain) natriuretic peptide. A positive cor-
relation has previously been established between plasma levels of B-
type (brain) natriuretic peptide (BNP), LVMI, and clinical outcome after
AVR.26-30 After appropriate informed consent was obtained, venous
blood for plasma BNP was drawn (along with routine blood work)
from patients’ antecubital veins. Samples were collected into chilled eth-
ylenediamine tetraacetic acid Vacutainer test tubes, after which plasma
separation was performed at4 C. Plasma samples were frozen at70
C until assay. BNP was determined by using a commercially available
fluorescence immunoassay (Biosite Diagnostics, Inc, San Diego, Calif).
Relation of BNP levels to echocardiographic and clinical outcomes was
studied.
Data Analysis
All data were entered and managed in a FoxPro (Microsoft Corp, Seattle,
Wash) database and analyzed with SAS software (SAS Institute, Inc, Cary,
NC).
Primary outcome. The regression of LVMI as measured with 2D
echocardiography (and confirmed with MRI) was the primary outcome in
this follow-up study. LV mass regression was calculated by subtracting
the mass index at follow-up from the mass index preoperatively. A mixed
linear model was used to account for both varying lengths of follow-up
and censoring because of death or reoperation.
Secondary outcomes. Secondary end points included transvalvular
gradients (both at rest and exercise), EOAs, transvalvular flow profiles,
functional outcome (by means of DASI and NYHA classification), and
plasma BNP concentrations. Analyses of echocardiographic and dynamic
MRI measurements, as well as DASI scores of functional capacity, were
undertaken by using a mixed linear model, as above. LV mass was com-
pared across all modalities by using a Pearson correlation coefficient.
Plasma BNP measurements were compared between groups with the Stu-
dent’s t test.
Clinical outcomes, such as survival, were determined by means of Ka-
plan–Meier analyses. The SPV and CE groups were compared with the
log-rank test. Similar analyses were performed for freedom from reopera-
tion and nonfatal valve-related events, including structural valve deteriora-
tion, reoperation, nonstructural dysfunction, thromboembolism, and
endocarditis. Multivariable predictors of the secondary outcomes were de-
termined by using parametric methods (Wiebull function). Relevant risk
factors, including demographic and preoperative variables, were entered
into the model in addition to valve type (SPV or CE) to determine the effect
of valve selection on survival, adjusting for other confounding factors/effect
modifiers. Multiple linear regression was performed to identify the role of
various preoperative predictors and prosthesis type on the secondary out-
comes.RESULTS
Ninety-nine patients were initially randomized in this pro-
spective trial. Preoperative clinical characteristics, including
age, body surface area, NYHA functional class, hyperten-
sion, the presence of coronary artery disease, and LV grade
were similar between groups (Table 1). Post hoc assessment
of implanted valve frequencies revealed that surgeons were
extremely consistent in selecting similar valve sizes for
a given annular diameter, regardless of prosthesis type.
However, despite an apparent difference in mean implanted
valve sizes between groups (based on manufacturer’sery c April 2010
TABLE 2. Characteristics of patients available for echocardiographic
follow-up
CE (n ¼ 17) SPV (n ¼ 21) P value
Age (y) 75.9  9.2 79.5  5.9 .22
Age>70 y 12 (71%) 14 (67%) .65
Female sex 7 (41%) 3 (14%) .14
CHF 0 2 (9%) .50
Diabetes 0 1 (5%) 1.00
Hypertension 7 (41%) 12 (48%) .65
CRF 0 0 1.00
CCS class III–IV 0 0 1.00
COPD 1 (6%) 2 (9%) .76
PVD 0 2 (9%) .50
Ejection fraction, n (%)
>60% 14 (82) 15 (71)
40%–59% 2 (12) 5 (24)
20%–39% 1 (6) 1 (5)
<20% 0 (0) 0 (0) .46
NYHA class, n (%)
I 14 (82) 15 (71)
II 3 (18) 6 (29)
III 0 (0) 0 (0)
IV 0 (0) 0 (0) .11
CE, Carpentier–Edwards pericardial bioprosthesis; SPV, Toronto Stentless Porcine
Valve; CHF, congestive heart failure; Diabetes, insulin-dependent or non–insulin-de-
pendent diabetes mellitus; Hypertension, documented history of treatment for hyper-
tension; CRF, chronic renal failure; CCS, Canadian Cardiovascular Society; COPD,
chronic obstructive pulmonary disease; PVD, peripheral vascular disease; NYHA,
New York Heart Association functional class.
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mm; P ¼ .0001), actual valvular internal diameters were
not significantly different in the 2 groups (CE, 21.9  2.0
mm; SPV, 22.3  2.0 mm; P ¼ .286). Furthermore, the in-
cidence of patient–prosthesis mismatch (EOA/body surface
area,<0.75 cm2/m2) was not significantly different between
groups (CE, 11%; SPV, 13%; P ¼ 1.00).
Perioperative morbidity and mortality were not differ-
ent between groups, with 4 early deaths recorded. Of
the 2 early deaths in the CE group, one was related to
stroke, and the other was related to myocardial infarction
after injury to the right coronary artery. Cause of death in
the patients with SPVs was endocarditis, leading to mul-
tisystem organ failure in 1 patient and brainstem infarc-
tion in another. Mortality at late follow-up was similar
in the 2 groups, with 11 (20.8%) recorded deaths in the
CE group and 8 (17.3%) recorded deaths in the SPV
group (P ¼ .49) at 12 years.
Patient characteristics at follow-up are presented in
Table 2. Late clinical follow-up was 82% complete at
a mean of 10.3 years postoperatively (range, 7.5–12.2
years). Mean age at follow-up was 75.9  9.2 years in the
CE group and 79.5  5.9 years in the SPV group. Non–
valve-related variables that might have adversely affected
overall patient well-being or functional capacity were not
different between groups (Table 2).The Journal of Thoracic and CaThirty-eight patients (CE group, n ¼ 17; SPV group,
n¼ 21) were available for late echocardiographic evaluation
at a mean of 9.3 years postoperatively (range, 7.5–11.1 yrs).
Table 3 displays the early and late echocardiographic out-
comes only in those patients available for both early and
long-term follow-up. Comparison with early outcomes pre-
viously published for the entire group demonstrated similar
trends out to 1 year postoperatively; however, there were
significant differences at 9 years.18
EOAs increased significantly in both groups during the
first postoperative year, with initial improvement occurring
primarily during the first 3 months after surgical intervention
(effect of time, P ¼ .0001). No differences in EOAs were
demonstrated between groups at 3 months (P ¼ .392) or
12 months (P ¼ .606) postoperatively. The mean EOA at
1 year was 1.88  0.56 cm2 in the CE group and 2.02 
0.76 cm2 in the SPV group (P ¼ .606). However, whereas
EOAs decreased significantly in the CE group thereafter,
EOAs remained stable in the SPV group with time. At 9
years, mean EOA was 1.49  0.59 cm2 in the CE group
and 2.00  0.53 cm2 in the SPV group (P ¼ .002). Overall,
no significant effects were demonstrated for the treatment-
by-time interaction (group 3 time effect, P ¼ .0.331). Fur-
thermore, echocardiographers were unable to identify any
consistent anatomic or qualitative differences between
valves to account for the observed quantitative differences
in EOAs.
Mean and peak transvalvular gradients decreased sig-
nificantly over the first year in both groups, once again
with most of the initial improvement occurring during
the first 3 postoperative months (effect of time, P ¼
.0001 in both groups). Although mean and peak gradi-
ents were lower in patients with SPVs at 3 months
(mean, P ¼ .035; peak, P ¼ .022), no differences in
gradients were noted at 1 year (mean, P ¼ .240; peak,
P ¼ .197).
After 1 year, mean and peak transvalvular gradients in-
creased in both groups, although to a greater degree in the
CE group. At 9 years, mean gradients were 10.86  3.7
mm Hg in the CE group and 7.47  4.3 mm Hg in the
SPV group (P ¼ .027), whereas peak gradients were 20.38
 6.5 mm Hg in the CE group and 14.59  7.1 mm Hg in
the SPV group (P¼ .025). Such differences were magnified
with dobutamine administration (mean: CE, 22.7  6.1 mm
Hg; SPV, 15.3  8.4 mm Hg; P ¼ .008; peak: CE, 48.1 
11.8 mm Hg; SPV, 30.8 17.7 mm Hg; P¼ .001). Overall,
no significant effects were demonstrated for the treatment-
by-time interaction (group 3 time effect: mean, P ¼ .900;
peak, P ¼ .456).
Measures of LV function were similar between groups,
improving in all patients over time. At 9 years, 94% of pa-
tients in the CE group and 95% of patients in the SPV group
exhibited ejection fractions of 40% or greater. Ejection frac-
tions normalized in both groups after dobutaminerdiovascular Surgery c Volume 139, Number 4 851
TABLE 3. Echocardiographic parameters and DASI scores in follow-up patients
Preoperative 3 mo 1 y 9 y P value (1 y vs 10 y) P value (group 3 time)
EOA (cm2)
CE 0.754  0.228 1.53  0.48 1.88  0.56 1.492  0.599 .040
SPV 0.775  0.20 1.75  0.84 2.02  0.76 2.000  0.532 .933 331
P value .791 .392 .606 .002
Mean gradient (mm Hg)
CE 54.60  16.3 10.39  4.8 7.06  3.7 10.86  3.7 .015
SPV 53.56  12.3 6.96  3.1 5.59  2.9 7.47  4.3 .145 900
P value .850 .035 .240 .027
Peak gradient (mm Hg)
CE 84.04  23.8 18.16  7.8 12.70  6.4 20.36  6.27 .005
SPV 88.72  30.9 12.25  5.0 9.92  4.8 14.59  7.14 .032 .456
P value .640 .022 .197 .025
Fractional shortening (%)
CE 38.42  10.6 33.20  7.8 39.35  7.6 27.07  9.7 .023
SPV 33.61  9.2 35.85  12.1 40.70  6.1 28.65  10.3 <.001 .212
P value .214 .509 .615 .667
LVMI (g/m2)
CE 133.70  29.4 119.58  34.8 115.36  35.9 111.22  21.4 .762
SPV 128.64  45.4 114.68  23.8 109.99  5.25 102.60  22.8 .395 .619
P value .711 .652 .639 .369
LVIDd (mm)
CE 42.92  9.2 43.50  6.4 43.92  6.7 40.79  12.0 .431
SPV 48.88  6.8 47.86  5.8 46.82  6.1 45.29  8.1 .536 .742
P value .050 .069 .235 .222
LVIDs (mm)
CE 27.58  9.3 28.69  6.6 26.36  5.9 32.43  8.6 .057
SPV 33.25  8.6 30.50  6.2 27.63  4.9 32.5  9.6 .319
P value .108 .470 .551 .976 .075
IVSd (mm)
CE 15.00  2.8 14.42  3.2 13.50  3.1 14.1  4.5 .670
SPV 13.82  2.5 12.86  2.4 12.59  1.97 11.9  1.5 .292 .845
P value .240 .155 .337 .089
DSE mean gradient (mm Hg)
CE 22.7  6.1
SPV 15.3  8.4
P value .008
DSE peak gradient (mm Hg)
CE 48.1  11.8
SPV 30.8  17.7
P value .001
DASI (mm)
CE 13.91  8.3 24.01  14.3 24.93  20.0 25.00  19.5 .999
SPV 14.12  10.1 20.53  12.0 28.35  6.4 19.86  12.0 .004 .471
P value .953 .466 .586 .423
DASI, Duke Activity Status Index; EOA, effective orifice area; CE, Carpentier–Edwards pericardial bioprosthesis; SPV, Toronto Stentless Porcine Valve; LVMI, left ventricular
mass indexed on body surface area; LVIDd, left ventricular internal dimension at end-diastole; LVIDs, left ventricular internal dimension at end-systole; IVSd, interventricular septal
thickness at end-diastole; PWTd, posterior wall thickness at end-diastole; DSE, dobutamine stress echocardiography.
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Dadministration, with 100% of the patients in both groups ex-
hibiting ejection fractions of greater than 60%. Overall, no
evidence of localized or global wall motion abnormality
was noted with dobutamine administration. Percentages of
fractional shortening, although similar in the 2 groups at 9
years, decreased over time, with significant improvement
after dobutamine administration.852 The Journal of Thoracic and Cardiovascular SurgLV mass indexed on body surface area (LVMI) was sim-
ilar in the 2 groups at baseline (CE, 133 g/m2; SPV, 128 g/m2;
P¼ .711). Mass regression continued in both groups out to 9
years, with most of the early effects occurring during the first
3 postoperative months (effect of time, P ¼ .0001 in both
groups). However, no differences in mass regression were
shown between groups at either 3 months (P ¼ .652) or 12ery c April 2010
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FIGURE 1. Regression of left ventricular mass index (LVMI). CE, Car-
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nificant early size-related advantage in patients with small
(23 mm) aortic annuli (LV mass regression for annuli
23 mm: CE, 23.3 g/m2; SPV, 24.2 g/m2; P ¼ .6381).
After 1 year, ventricular mass continued to regress slightly
in both groups, although not to a significant degree. At 9
years, LV mass regression was 22.48 g/m2 in the CE group
and 26.04 g/m2 in the SPV group (P¼ .393). Overall, no sig-
nificant effects were demonstrated for the treatment-by-time
interaction (group 3 time effect, P ¼ .619; Figure 1).
Cardiac MRI confirmed the echocardiographic LV mass
findings. At 9 years, MRI-generated LVMI was 100.13 
38.3 g/m2 in the CE group and 103.22  29.0 gm/m2 in
the SPV group (P ¼ .86). Among patients who underwent
both echocardiographic and MRI assessments, measures of
LV mass were found to be highly correlative (r ¼ 0.91,
P ¼ .001).
Plasma BNP concentrations were similar in the 2 groups,
although highly variable (CE, 98.11  82.6 pmol/L; SPV,
106.30  96.1 pmol/L). Overall, plasma BNP concentra-
tions were found to correlate strongly with LVMI (r ¼
0.66, P ¼ .003). No correlation was found with mean/peak
gradients or DASI/NYHA scores. Patients with significant
aortic insufficiency (AI) at follow-up were more likely to
have BNP concentrations in excess of 200 pmol/L.
DASI scores improved significantly over the first year in
both groups (P¼ .0001). At 1 year, patients with CEs scored
24.93  10.0, whereas patients with SPVs scored 28.35 
6.4 (P¼ .586). After 1 year, DASI scores of functional status
remained relatively stable in patients with CEs while de-
creasing in patients with SPVs, although the difference
was not statistically significant (CE, 25.00  9.5; SPV,
19.86  12.0; P ¼ .423). Overall, no significant effects
were demonstrated for the treatment-by-time interaction
(group 3 time, P ¼ .471; Table 3).
A similar trend was demonstrated with respect to NYHA
functional status, which improved significantly over time inThe Journal of Thoracic and Caboth groups. At 9 years, 100% of patients in both groups
were in NYHA functional classes I or II (Table 2).
Aortic root dilatation (>3.5 cm) was observed in 2
patients (CE, 1; SPV, 1) at follow-up. In the CE group 6
patients exhibited mild AI, with 1 patient exhibiting mild-
to-moderate AI (aortic root diameter, 3.4 cm). In the SPV
group 4 patients exhibited mild AI, 2 patients exhibited
mild-to-moderate AI (aortic root diameter, 3.4 and 3.5 cm,
respectively), and 1 patient exhibited moderate-to-severe
AI (aortic root diameter, 3.8 cm).
Actuarial freedom from reoperation was similar in both
groups out to 9 years; however, it dropped off in stentless
patients thereafter (CE, 92%  5%; SPV, 75%  5%;
P ¼ .65; Figure 2). Among patients requiring reoperation,
5 had documented structural valve dysfunction. One pa-
tient in the CE group underwent reoperation for prosthetic
valve endocarditis, with significant AI documented before
infection, whereas 4 patients in the SPV group required
reoperation for severe valvular dysfunction, with resultant
stenosis or regurgitation. Findings during surgical inter-
vention included leaflet vegetations and tears in the pa-
tient with a CE and leaflet calcifications and tears in the
patients with SPVs. Two patients in the SPV group re-
quired reoperation for nonstructural valve dysfunction.
Findings in these patients included leaflet tears associated
with dilatation of the sinotubular junction. All patients
survived reoperation, with no significant perioperative
complications.
Actuarial freedom from valve-related morbidity was
82%  5% in the CE group and 55%  5% in the
SPV group (P ¼ .05, Figure 3). Valve-related events in-
cluded 1 patient with endocarditis and 3 patients with
thromboembolic episodes in the CE group versus 2 pa-
tients with endocarditis and 5 patients with thromboem-
bolic episodes in the SPV group. Finally, actuarial
survival (freedom from all-cause mortality) was 35% 
7% in the CE group and 52%  7% in the SPV group
(P ¼ .37, Figure 4).rdiovascular Surgery c Volume 139, Number 4 853
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The suggested hemodynamic superiority of stentless
valves has been well documented in various reports over
the past decade. Unfortunately, most studies are retrospec-
tive, some from trial databases, others case matched, and
only a few prospectively randomized with attention to true
annular and valvular dimensions. Even among published
randomized trials, no unified message has evolved. In a re-
cent trial by Ali and colleagues,31 161 patients were random-
ized to receive either the Edwards Prima stentless
bioprosthesis or the Carpentier–Edwards Perimount stented
bioprosthesis. Although the mean implanted valve size was
larger in the stentless group, at 8 weeks postoperatively, no
differences in transvalvular gradients or ventricular mass
were noted between groups. Similarly, in an article by
Chambers and coworkers,14 among 160 patients randomized
to receive either the Edwards Perimount stented valve or the
SPV, no significant differences were demonstrated in hemo-
dynamic function or clinical events up to 5 years postopera-
tively. Conversely, in a trial by Perez de Arenaza and
assoociates32 in which 191 patients were randomized to
stented or stentless valves, significant benefits in both in-
dexed EOA and peak flow velocity were demonstrated in
the stentless valve group. Finally, in a study by Dunning
and associates,33 among 60 patients randomized to either
the Sorin Freedom stentless or the Sorin More stented bio-
prostheses, lower peak gradients and greater EOAs were
shown in the stentless group. These differences were also
associated with earlier regression of LV hypertrophy.
The above shows the great disparity and limitation inher-
ent in contemporary randomized trials of stentless versus
stented valves. Perhaps the closest to some form of consen-
sus has come from 2 recent publications. A meta-analysis of
10 published randomized trials involving a total of 919 pa-
tients performed by Kunadian and colleagues16 concluded
that stentless aortic valves provide reduced aortic gradients854 The Journal of Thoracic and Cardiovascular Surgand an improved EOA index at the expense of a 23-minute
longer crossclamp time and a 29-minute longer bypass time.
Although LV mass regression in patients receiving stentless
valves was superior at 6 months, ultimate regression of LV
mass at 1 year postoperatively was not different between
groups. Similarly, a meta-analysis by Raja and coworkers34
concluded superior early hemodynamic performance of
stentless valves. However, the effect on LV mass regression
was found to be similar for both stented and stentless valve
types. The authors concluded that this finding might have
been due to improved performance of second- and third-
generation stented valves.
Notwithstanding such reports, the above findings raise
a number of important questions. First, are previously
published negative studies limited by their relatively short
duration of follow-up, such that late advantages in hemody-
namics, LV mass, and/or clinical outcome are unapparent?
Would seemingly minor differences in hemodynamics be
augmented under conditions of stress? With respect to
positive studies, are the early reported hemodynamic bene-
fits of stentless valves maintained long-term? Do such
hemodynamic differences translate into improvements in
functional status, clinical outcome, or both?
To date, the longest documented follow-up of randomized
patients is a midterm assessment performed by Lehmann and
associates35 involving patients assigned to receive either
stentless (SPV or Freestyle) or stented (CE) valves. At
a mean of 6.9 years postoperatively, patients in the stentless
group demonstrated lower transvalvular flow velocities and
improved survival, albeit with no correlation to transvalvular
gradients.
The current study was designed as a long-term follow-up
of patients previously randomized in our original trial of
stentless versus stented valves. Although no differences in
hemodynamic or clinical outcomes were demonstrated at 1ery c April 2010
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hibited superior hemodynamic performance.
Most currently available bioprostheses have acceptable
hemodynamic indices at rest. However, as cardiac output
increases (ie, with exercise), valvular flow profiles and, in
particular, transvalvular gradients might change accord-
ingly.36-38 In light of the aforementioned, we chose to eval-
uate our patients using dobutamine stress echocardiographic
analysis to simulate conditions of exercise. In doing so, the
differences between groups were magnified, such that gradi-
ents increased more significantly in the CE group versus
those in the SPV group.
Although such findings appear significant at first glance,
the question remains: do such hemodynamic differences
translate into differences in LV mass or functional/clinical
outcome?
Ventricular hypertrophy has long been known to correlate
strongly with poor long-term outcomes.39–41 Although ven-
tricular mass regression can be detected as early as 1 week
after AVR, regression has been documented well into the
fifth postoperative year.42
In the current patient population, indexed LV mass re-
gressed significantly in both groups over time, with most
of the early effect occurring during the first 3 postoperative
months. However, no differences in mass regression were
found between groups either at 1 or 9 years postoperatively.
These findings were confirmed through MRI studies and
were further supported by plasma BNP measurements,
which correlated highly with measurements of ventricular
mass. This finding is of particular interest in light of similar
reports indicating a correlation with transvalvular gradients
and long-term survival.43–45 Although 50% of patients in ei-
ther group were hypertensives, all such patients were suc-
cessfully managed medically, as confirmed on trial
enrollment and during follow-up appointments, thus limit-
ing the potential effect on mass regression.
Functional outcomes in this study were determined by
using well-described methods. Because the risk of cardiac
morbidity and mortality associated with stress testing in pa-
tients with critical aortic stenosis precludes its preoperative
use, we used the DASI score to evaluate functional capacity.
As a clinical outcome proxy for exercise capacity, DASI
scores permitted the evaluation of functional status and qual-
ity of life with a comparison with NYHA status. By using
such methods, no differences in functional outcome were
demonstrated between groups.
Similarly, although our study was underpowered for the
detection of differences in mortality, no obvious survival
differences were noted between groups. Such findings
were in keeping with those reported by Lehmann and col-
leagues35 in their midterm follow-up of randomized patients
receiving stentless devices, in whom hemodynamic differ-
ences did not correlate with clinical or functional outcomes.
Although survival differences were noted between groups,The Journal of Thoracic and Casuch differences were not found to be valve related and
did not correlate with transvalvular gradients.
Yet additional benefits have been attributed to stentless
valves. One such benefit is that of improved coronary flow
reserve, possibly caused by reduced turbulence downstream
to a stentless valve during systole and improved backflow dur-
ing diastole.44-48 Although an attempt was made to measure
coronary flow in the current study by using velocity-encoded
MRI, results were highly variable and thus uninterpretable.
Nonetheless, with dobutamine administration, ventricular
function normalized in all patients with no demonstrable
wall motion abnormalities, indicative of normal or near-
normal coronary perfusion in the 2 groups.
Another supposed advantage of stentless valves might
be that of superior durability. The inherent flexibility of
a stentless valve theoretically takes advantage of the
dynamic nature of the aortic annulus, which might vary
considerably during the cardiac cycle.49 Implantation of
a stentless valve within the native aortic root might thus
facilitate normal leafletmotion during systole, with a dampen-
ing of mechanical stresses and turbulence during diastole.
This, in turn, might result in enhanced durability over time
with fewer valvular complications at follow-up.50
With dynamic MRI assessment, we were unable to dem-
onstrate any significant changes in annular dimension be-
tween systole and diastole in either group. This might
indicate annular fixation with prosthetic valvular replace-
ment, regardless of valve type. Such findings are in keeping
with a previously published report by Kazui and associ-
ates,51 who evaluated the motion of the aortic root in healthy
volunteers using multidetector computed tomographic anal-
ysis. Although in the normal aortic root no part of the aortic
annulus changed length during the cardiac cycle, the com-
missural regions were found to move outward during the
systolic phase. This finding might be important in the selec-
tion of stentless valve implantation technique because dy-
namic changes in the aortic root might place undue stress
on the leaflets of stentless valves implanted by using the sub-
coronary method.
Irrespective of annular motion, subcoronary stentless valve
implantation creates an intimate relationship between aortic
dimension and valvular dynamics, which might affect valvu-
lar durability. In the current study, valvular insufficiency in
patients receiving stentless valves seemed to be related to
changes in aortic root diameter. This finding was consistent
with reports previously published by our group and others
documenting an increased prevalence of prosthetic nonstruc-
tural valve dysfunction in patients receiving SPVs when there
is dilatation of the sinotubular junction.52,53
Such limitations along with the variable hemodynamic
benefits of subcoronary implants have prompted some sur-
geons to adopt a policy of full root replacement for isolated
aortic valve disease. However, although improved hemody-
namic indices and outcomes have been reported,54,55 suchrdiovascular Surgery c Volume 139, Number 4 855
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by complicating an otherwise simple operation.56
In the current study freedom from reoperation was similar
between groups up to 9 years postoperatively. Thereafter, re-
operation was more prevalent in patients receiving SPVs.
Although in these cases the reoperative courses were uncom-
plicated, it must be noted that reoperation for stentless valve
explantation has generally been found to be somewhat more
complicated than that for stented valve explantation and in
some cases has been shown to be associated with an in-
creased risk of death.55LIMITATIONS
Although our original study was randomized in nature,
patient numbers were too small to enable any definitive con-
clusions regarding group-related differences in long-term
mortality or clinical outcome. Furthermore, the current study
does not take into account newer generations of stented val-
vular prostheses and might not be generalizeable to patients
who have undergone AVR with other types of stentless
valves. Finally, this study did not address potential advan-
tages of one valve type over another in cases of abnormal
ventricular function.CONCLUSIONS
In conclusion, our findings reaffirm the need for long-term
follow-up to evaluate valve-related outcomes. With regard
to the current study, although short-term follow-up did not
show any differences between stentless and stented valves,
with longer-term follow-up, stentless valves were found to
outperform their stented counterparts, both at rest and with
exercise. However, such improvements did not translate
into functional or clinical benefit up to 12 years after implan-
tation and did not affect durability or LV mass regression. In
light of these and similar reports, our current practice is to
use stentless valves only when full root replacement with
a bioprosthesis is indicated.
These findings raise interesting questions with respect to
the true impact of hemodynamic differences between valve
types. Although EOAs and gradients are crucial in evaluat-
ing valve function, patient responses vary, and clinically sig-
nificant thresholds have yet to be conclusively identified.
That being the case, in assessing the benefits of a particular
valve design, the goal should be a comparison of clinical
outcomes, such as survival, freedom from valve-related
morbidity, and functional capacity rather than EOAs, gradi-
ents, and patient–prosthesis mismatch.
Finally, both stented and stentless designs were found to
be suitable options for AVR. Nonetheless, in selecting
a stentless valve, surgeons must evaluate any potential ben-
efits of stentless design against the risks of longer procedural
times and more complex reoperations, especially in the face
of continued improvements in stented design.856 The Journal of Thoracic and Cardiovascular SurgReferences
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Dr Hartzell V. Schaff (Rochester, Minn). Thank you, Dr Miller,
DrKron. I want to congratulate DrCohen on a beautiful presentation.
He and his colleagues have provided important information on the
10-year follow-up of a comparative study of the stented and stentless
valves. He has shown no difference in the mass regression when
comparing the 2 groups. There is no real difference in hemodynam-
ics, perhaps a 3-mm gradient, which was statistically significant but
appears not to be clinically important. The most important feature is
that there does not appear to be a difference in clinical outcome.
The limitations of the study are clear. It is a small group of pa-
tients, but I think that the strengths should be emphasized. If there
is anyone from the US Food and Drug Administration here or if any
of our colleagues consult for the Food and Drug Administration,
this is really a model for how valve studies should be performed.
It is randomized, and importantly, the patients are stratified accord-
ing to annular diameter and not to labeled valve size.
I have a few questions. Dr Miller asked that we take these in or-
der. You found no difference in mass regression between the
stented and stentless valves, but did you do any analysis that looks
at the predictors of mass regression in the overall group? For exam-
ple, is there any subgroup that might benefit from this small 3-mm
gradient difference, such as those with more severe degrees of hy-
pertrophy or hypertension?
Dr Cohen. We actually did, and although there was a slight
beneficial trend in female subjects, in general, the numbers were
too small to enable any conclusive statements.
Dr Schaff. And you found that the regurgitant orifice areas in the
stentless group improved over time, but that was at the expense of
an increased degree of aortic regurgitation in that group. Did you
analyze valve areas in patients who had no aortic regurgitation at
the end of follow-up?
Dr Cohen. I would say specifically no. However, we did ex-
clude patients who had either moderate to moderate–severe aortic
regurgitation. Therefore all of the patients we included in the echo-
cardiographic follow-up had little or no residual AI. Those who didrdiovascular Surgery c Volume 139, Number 4 857
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nate the findings with patients who had some evidence of valve dys-
function or valve deterioration.
Dr Schaff. It is also an interesting study in one final regard, and
that is that it seems the most important findings are not the differ-
ences that are statistically significant but perhaps a nonsignificant
difference that is clinically important; that is, the appearance that
there is decreased durability of the stentless valves. The stentless
valves were introduced with the idea that the flexibility might im-
prove long-term durability. Can you comment on why you found
the opposite?
Thank you.
Dr Cohen. Thank you, Dr Schaff. One of the things we did look
at through MRI assessment was the flexibility of the aortic annulus
after stented versus stentless valve implantation. The feeling was
that when we initially implanted these valves there would be
more flexibility in patients receiving stentless valves and that this
would translate to improved durability. In fact, we were not able
to find any differences or changes in the configuration of the annu-
lus by MRI assessment.
As to why the patients receiving stentless valves had poor dura-
bility over time, there are 2 reasons. First, when the Toronto stent-
less porcine valve was initially introduced, there was no
anticalcification treatment. Therefore, we found that our patients
with stentless valves tended to have calcification of the leaflets
somewhat earlier than those receiving pericardial valves. The other
issue is that when we initially implanted the stentless valve, we
really did not think much about the interrelation of a subcoronary
implant with the aortic root. Obviously what we found, especially
in patients with bicuspid aortic valves who were prone to aortic root
dilatation over time, was that displacement of the commissures of
the stentless valve caused eventual leaflet tears or what we define
in our study as nonstructural valve dysfunctions. Those 2 issues
were the ones that I think contributed to most of the failures in
the patients receiving stentless valves.
Dr. D. Craig Miller (Stanford, Calif). Gideon, I might have
missed it, but for which primary end points is this study adequately
powered statistically to support this conclusion of no difference? Is
there a chance of a type 2 or b error here?
Dr Cohen. That is an excellent question. We were underpow-
ered to make any definitive conclusions with respect to clinical out-
comes. There is no question about that. Our primary and secondary
outcomes were LV mass regression and functional outcome based
on the DASI score, and we were adequately powered for those 2
outcomes.
Dr Joseph E. Bavaria (Philadelphia, Pa). I would amplify what
Dr Schaff said about the beauty of this prospective randomized
study. It was very nicely done and produced great 9-year data.
We will learn a lot from it.
My question really is regarding the same thing Dr Schaff talked
about, which is structural valve deterioration for this subcohort you858 The Journal of Thoracic and Cardiovascular Surghave presented. There are fairly reasonable data coming out on the
Freestyle root, as well as the full root Toronto valve, that if you per-
form full root operations, you do not get these structural valve de-
teriorations that you see in your study. Therefore I would like for
you to comment on the controversy regarding full root versus sub-
coronary stentless implantation and as it pertains to early and mid-
term structural valve deterioration.
Dr Cohen. Thank you very much. That is an excellent question
once again. There has been a lot of talk advocating full root replace-
ments for isolated aortic valve disease, and there have been some
series that have reported excellent outcomes with equal morbidity
and mortality to that of just plain old aortic valve replacement.
To be honest with you, I am not sure we should be advocating
full root replacement for isolated aortic valve disease. To me, that
is tantamount to recommending total colectomy for acute appendi-
citis. It does not make much sense. Although there are certain
groups that I am sure can achieve excellent outcomes, I am not
sure that the average surgeon, myself included, is willing to submit
his patients, most of whom are now 70 to 80 years of age or older, to
full root replacement for isolated aortic valve disease, especially in
the absence of definitive clinical evidence of benefit with stentless
valves and a full root replacement.
Dr Thoralf Sundt (Rochester, Minn). Because you are looking
at LV mass regression, and maybe you mentioned this and I missed
it, a lot of your patients have hypertension, and we are well aware
that hypertension can have as profound an effect on LVmass as the
valve itself. How did you go about evaluating the adequacy of an-
tihypertensive therapy in the 2 groups, are you sure that they were
similar, so on and so forth?
Thank you very much.
Dr Cohen. We initially stratified our study by annular diameter,
coronary disease, and surgeon. We did not stratify by hypertension
because it is very difficult to diagnose or to definitively say that a pa-
tient has hypertension preoperatively because high blood pressure
might be a physiologic response to aortic stenosis. Therefore we
did not stratify ahead of time, and we hoped—and in fact it was
the case because of the randomized nature of this study—that there
were an equal number of hypertensive patients in both groups; ac-
tually, they were identical percentages.
I think that there is no question that hypertension—ongoing
hypertension—might have had an effect; however, for all of our
patients who were followed, we confirmed adequate control of
hypertension postoperatively through frequent visits and close
follow-up with cardiologists.
Dr Miller. I have one little bit of unsolicited advice worth ex-
actly zero pesos. That MRI on the right, I will bet you a 6-pack
that was a bicuspid valve and you should have replaced the tubular
segment of the ascending aorta.
Dr Cohen. You are probably right. Thanks.
DrMiller. Left a little guppy aneurysm behind in the context of
bicuspid aortic valve disease.ery c April 2010
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DAppendix 1. Echocardiographic parameters and
calculations
EOA
By reconfiguration of the continuity equation, aortic EOA is cal-
culated as follows:
EOA ¼ ðCASLVOT3TVILVOTÞ=TVIAO

cm2

;
where CSALVOT is defined as left ventricular outflow tract
(LVOT) cross-sectional area (pR2/4) in square centimeters
obtained from 2Dmeasurement of LVOT diameter; TVILVOT
is defined as the time velocity integral of forward blood flow
in centimeters derived from pulsed-wave (PW) Doppler
scanning in the LVOT; and TVIAO is defined as the time ve-
locity integral of forward blood flow in centimeters derived
from transvalvular continuous-wave (CW) Doppler scan-
ning.Cardiac output
Cardiac output (CO) is calculated by using the following for-
mula:
CO ¼ ðTVILVOT3CSALOVTÞ x HRðin L=minÞ;
where TVILVOT is defined as the time velocity integral of for-
ward blood flow in centimeters derived from PW Doppler
scanning in the LVOT; CSALVOT is defined as the LVOT
cross-sectional area (pR2/4) in square centimeters obtained
from 2Dmeasurement of LVOT diameter; andHR is defined
as heart rate in beats per minute.Peak pressure gradient
Peak velocities obtained from PW and CWDoppler scanning are
converted into pressure gradients by using Bernoulli’s equation as
follows:
DPPEAK ¼ 4

V22V21

for an aortic valve peak systolic
pressure gradient in millimeters of mercury;
where V2 is defined as peak transvalvular velocity in meters
per second asmeasured with CWDoppler scanning and V1 is
defined as peak velocity in the LVOT in meters per second,
as measured with PW Doppler scanning.Mean pressure gradient
Mean transvalvular pressure gradient is calculated by subtrac-
tion of the mean pressure proximal to the aortic valve from theThe Journal of Thoracic and Camean distal pressure. Mean pressures are obtained by means of
planimetry of the Doppler spectral envelope.
DPMEAN ¼ ðP2P1Þ;mean transvalvular pressure gradient
in millimeters of mercury;
where P2 is defined as mean distal pressure in millimeters of
mercury, as measured with CW Doppler scanning, and P1 is
defined as mean pressure in the LVOT in millimeters of
mercury, as measured with PW Doppler scanning.
LV mass
LV mass ¼ 0:831:043ðLVIDdþPWTdÞ3ðLVIDdÞ3
þ0:6g;
where LVIDd is defined as LV internal dimension at end-
diastole in centimeters; IVSd is defined as interventricular
septal thickness at end-diastole in centimeters; and PWTd
is defined as posterior wall thickness at end-diastole in
centimeters.
*This formula for LV mass is based on the volume-corrected
ASE cube method.10
LV function
The percentage of fractional shortening, when derived from
M-mode measurements, is based on minor axis shortening and
assumes the ventricle contracts symmetrically.
%DD ¼ ðLVIDdLVIDSÞ=LVIDd3100%;
where LVIDd is defined as LV internal dimension at end-
diastole in centimeters and LVIDs is defined as LV internal
dimension at end-systole in centimeters.
Velocity of circumferential fiber shortening, when derived from
M-mode measurements, represents the velocity of fiber shortening
in the minor axis rather than in the whole circumference.
Vcf ¼ ðLVIDdLVIDsÞ=LVIDd3LVETÞin circumferences
per second
where LVIDd is defined as LV internal dimension at end-
diastole in centimeters; LVIDs is defined as LV internal
dimension at end-systole in centimeters; and LVET is
defined as LV ejection time in milliseconds measured
from the onset to the end of systolic flow.rdiovascular Surgery c Volume 139, Number 4 859
